ANGLE plc Announces Parsortix Potential in Metastatic Breast Cancer
GUILDFORD, SURREY--(Marketwired - Dec 8, 2017) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)
For immediate release | 8 December 2017 |
AIM:AGL OTCQX:ANPCY
ANGLE plc ("the Company")
GROUND-BREAKING WORK DEMONSTRATES POTENTIAL FOR PARSORTIX™ LIQUID BIOPSY TO REPLACE SOLID BIOPSY IN METASTATIC BREAST CANCER
Direct comparison of a simple blood test processed with the Parsortix system with invasive solid biopsy of the metastatic site delivers comprehensive gene expression analysis
Leading US cancer center, the University of Southern California Norris Comprehensive Cancer Center presents data at the world-renowned San Antonio Breast Cancer Symposium
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that the University of Southern California (USC) Norris Comprehensive Cancer Center yesterday presented results of extensive work with ANGLE's Parsortix™ system at the San Antonio Breast Cancer Symposium (SABCS) detailing how the system can be used to obtain comparable gene expression information from a simple blood test in place of an invasive solid tissue biopsy of a metastatic site.
USC made a direct comparison of extensive gene expression information from the biopsy of the metastatic site with that from a blood test processed with the Parsortix system. Information from the blood test using the Parsortix system "did not show significantly different patterns of expression" compared to the invasive biopsy of the metastatic site. 66 clinically actionable genes in 7 different signalling pathways were measured addressing the key areas that clinicians currently investigate.
ANGLE is working towards an FDA clearance of the Parsortix system in metastatic breast cancer with the required analytical and clinical studies targeted for completion by 30 June 2018. ANGLE is seeking to become the first company ever to receive FDA clearance for a medical device to harvest cancer cells from patient blood for subsequent analysis. The ground-breaking work presented by USC at SABCS demonstrates the importance of being able to harvest and analyse these cells from patient blood.